Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
Multikinase inhibitors (MKIs) targeting VEGF receptors and other receptor tyrosine kinases have shown considerable activity in clinical trials of thyroid cancer. Thyroid cancer frequently exhibits activation of the RAS/RAF/MEK/ERK pathway. In other types of cancer, paradoxical ERK activation has eme...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
D.A. Spandidos
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583528/ |